Investment Rating - The report maintains an investment rating of "Outperform" with a target price set for the leading stocks [7]. Core Insights - The National Healthcare Security Administration released the "Commercial Health Insurance Innovative Drug Directory (2025)", which includes 19 high-cost innovative drugs, including five CAR-T therapies and two Alzheimer's drugs. This is expected to improve payment difficulties for high-value innovative drugs and provide an additional payment pathway beyond basic medical insurance [3][24]. - The report highlights several promising stocks to watch, including those with high certainty for overseas expansion and those with potential overseas data catalysts [2][22]. Weekly New Drug Market Review - From December 1 to December 7, 2025, the new drug sector saw significant stock movements, with the top five gainers being Beihai Kangcheng (+13.94%), Maibo Pharmaceutical (+11.32%), Jiahe Biotech (+8.38%), Junsheng Tai (+7.14%), and Nuo Si Lan De (+6.27%). Conversely, the top five losers included Shengnuo Pharmaceutical (-15.18%), Shouyao Holdings (-9.06%), Boan Biotech (-8.62%), Tengsheng Bo Pharmaceutical (-8.05%), and Yiming Angke (-7.72%) [1][16]. New Drug Approval and Acceptance Status - This week, one new drug or new indication application was approved, and 16 new drug or new indication applications were accepted in the domestic market [4][28]. Clinical Application Approval and Acceptance Status - A total of 44 new drug clinical applications were approved, and 40 new drug clinical applications were accepted this week [5][31].

Core Viewpoint - Betta Pharmaceuticals has announced that several of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance the accessibility and market potential of these drugs [1] Group 1 - Betta Pharmaceuticals' products included in the 2025 drug list are: - Hydrochloride Alectinib Tablets (Kaimena) - Hydrochloride Ensartinib Capsules (Beimana) - Mesylate Bafetinib Capsules (Saimena) - Voronib Tablets (Fumeina) [1] - Additionally, the company's Bevacizumab Injection (Beanding) has been included in the National Medical Insurance Category B drug list [1]

Core Viewpoint - The announcement indicates that several products from the company have been included in the National Medical Insurance Drug List for 2025, which is expected to enhance accessibility and positively impact sales, although the exact effect on current performance cannot be accurately estimated [1] Group 1 - The products included are: - Hydrochloride Alectinib Tablets - Hydrochloride Ensartinib Capsules - Mesylate Bafetinib Capsules - Vorinostat Tablets These products will be effective from January 1, 2026, to December 31, 2027 [1] - Additionally, the product Bevacizumab Injection has been included in the National Medical Insurance Category B Drug List [1] Group 2 - Inclusion in the medical insurance list is expected to improve product accessibility [1] - The impact on sales is anticipated to be positive, although the company cannot currently provide an accurate estimate of the effect on its performance [1]

每经AI快讯，12月7日，贝达药业（300558）(300558.SZ)公告称，公司产品盐酸埃克替尼片(凯美纳)、 盐酸恩沙替尼胶囊(贝美纳)、甲磺酸贝福替尼胶囊(赛美纳)以及伏罗尼布片(伏美纳)被纳入《国家基本医 疗保险、生育保险和工伤保险药品目录(2025年)》。此次纳入将提高产品的可及性，对销售产生积极影 响。但对公司当期经营业绩的影响目前无法准确估计。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-075 贝达药业股份有限公司 关于公司产品纳入《国家医保药品目录》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 恩沙替尼是一种新型强效、高选择性的新一代 ALK 抑制剂，是公司和控股子 公司 Xcovery 共同开发的自主创新药。全球多中心Ⅲ期临床 eXalt 3 研究数据显示 一线治疗经独立评审委员会（IRC）评估 ITT 人群无进展生存期（PFS）为 31.3 个 月，12 个月内脑转移发生率 4.2%。2022 年 12 月 8 日，eXalt 3 研究亚裔更新数据 在 MSK-CTONG 中美交流会上公布，在基线无脑转移人群中恩沙替尼组 PFS 达 47.1 个月，亚裔人群中盐酸恩沙替尼完全缓解率（CR 率）为 15.1%。2025 年 10 月，恩沙替尼术后辅助治疗数据在欧洲肿瘤内科学会（ESMO）年会上首次披露， 中期结果显示，恩沙替尼术后辅助治疗 2 年无病生存期（DFS）率达 86.4%，2 年 无病生存期风险比（HR）为 0.20，复发风险降低 80%，显著减少了疾病复 ...

Group 1 - The report highlights a significant divergence in the performance of various sub-sectors within the pharmaceutical industry in 2025, with the CXO and innovative drug-related sectors showing substantial growth, while the medical service sector is expected to gradually recover in 2026 due to a low base effect from 2025 [2][6][58] - The overall performance of the A-share market was positive in 2025, with the pharmaceutical and biological sector ranking 10th with a growth of 34.95%, while the CXO sector led with a growth of 58.71% [6][15] - The report emphasizes the importance of "product-driven" companies, which are expected to enter a profitability cycle as they recover from the impacts of centralized procurement and increase their R&D investments [2][29] Group 2 - The innovative drug sector is projected to continue its upward trend, with business development (BD) opportunities abroad being a key focus, indicating the global competitiveness of Chinese innovative drugs [30][34] - The medical device sector is also expected to follow a similar recovery path as innovative drugs, with increasing R&D investments and a growing number of approved innovative medical devices [43][45] - The medical service sector, despite facing short-term pressures, is anticipated to gradually recover in 2026, supported by an aging population and increasing demand for healthcare services [58] Group 3 - The report suggests specific companies to watch in various sectors, including medical devices (e.g., Sanyou Medical, Aikang Medical), innovative drugs (e.g., Innovent Biologics, Kintor Pharmaceutical), and medical services (e.g., Aier Eye Hospital, Tongce Medical) [2][29] - The report notes that the pharmaceutical sector's overall valuation remains at a historical low, with a price-to-earnings ratio of 30.82 times as of October 31, 2025, indicating potential for upward adjustment [19][20] - The report highlights the importance of key product advancements and performance realization in the innovative drug sector, particularly for products like PD-1/VEGF, which have shown promising clinical data and significant market interest [39][40]

Core Viewpoint - The recent acceptance notice from the National Medical Products Administration (NMPA) regarding the cancer drug "BPI-572270" has raised questions among investors about the relationship between Betta Pharmaceuticals Co., Ltd. and the lesser-known Hangzhou Jingyao Biotechnology Co., Ltd., which submitted the clinical trial application for the drug [1][6]. Group 1: Drug Development and Clinical Trials - "BPI-572270" targets challenging KRAS mutations, which are responsible for various cancers, with a mutation frequency of 20%-30% across all cancers [4]. - Betta Pharmaceuticals claims that "BPI-572270" is a potent pan-RAS inhibitor, showing strong cytotoxic effects against tumor cells with different KRAS, NRAS, and HRAS mutations, demonstrating nanomolar-level IC50 cell activity [4]. - The drug has shown tumor regression in mouse models of pancreatic cancer with low-dose oral administration and has favorable pharmacokinetic properties and safety profiles in animal studies [4]. Group 2: Company Structure and Strategy - Jingyao Biotechnology, established on October 17, 2025, has expanded its business scope to include drug production and wholesale, raising questions about its independence from Betta Pharmaceuticals [6]. - The proximity of Jingyao Biotechnology to Betta's incubation platform, "Betta Dream Factory," suggests a potential strategic relationship, reflecting a trend in the Chinese pharmaceutical industry towards platform and ecosystem models [6][9]. - Betta Pharmaceuticals positions itself as a platform-based pharmaceutical company, emphasizing its capabilities in drug discovery, commercialization, and innovative ecosystems [6][9].

Group 1 - The core viewpoint of the article is that He Yuan Bio has established a commercial partnership with China National Pharmaceutical Group (Sinopharm) and other distributors to enhance its market presence and product promotion [1] - He Yuan Bio has signed distribution agreements with multiple pharmaceutical distributors, including Sinopharm and Betta Pharmaceuticals, completing a sales network layout across over 30 provinces and cities in China [1] - Sinopharm acts as a commercial partner for He Yuan Bio in specific regions, focusing on academic promotion, market expansion, and channel development to jointly enhance product market coverage and clinical application [1]

Group 1 - The core viewpoint of the article highlights the collaboration between He Yuan Bio and China National Pharmaceutical Group (Sinopharm) as a commercial partner in specific regions, focusing on product promotion and market expansion [1] - He Yuan Bio has established a sales network across more than 30 provinces and cities in China through agreements with multiple distributors, including Sinopharm and Betta Pharmaceuticals [1] - The company is actively engaged in academic promotion, market development, and channel construction with Sinopharm to enhance product market coverage and clinical application [1]

Group 1 - The company, Betta Pharmaceuticals (300558), is actively monitoring the developments of its partners in the innovation ecosystem and will disclose any significant collaborations in accordance with regulatory requirements [1]